louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03382002: Association Between Oxidative Parameters in Fertilization Medium of Cumulus Oocyte Complex and Outcome in IVF
Official title: Evaluation of Association Between Oxidative Parameters in Fertilization Medium of Cumulus Oocyte Complex (COC( as Measured by the TCL Assay and Clinical and Laboratory Outcome Parameters in IVF
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Oxidative Stress
Lead sponsor: Carmel Medical Center
Sponsor class: OTHER
First posted: 2017-12-22
Enrollment: 322
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing in vitro fertilization

Brief summary: Medium of cumulus-oocyte complex will be assessed for oxidative status.


Eligibility criteria: Inclusion Criteria:

•Patients undergoing in vitro fertilization treatment

Exclusion Criteria:

•Patients undergoing intracytoplasmic sperm injection

Primary outcomes:
measure: Association of parameters of oxidative state with cycle outcome (pregnancy: yes/no)
timeFrame: two years
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Carmel medical Center
Study officials:
References:
Clinical trial NCT01498302: Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia
Official title: Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Leukemia
Keywords: childhood acute myeloid leukemia/other myeloid malignancies
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2011-12-23
Enrollment: 10
Sex: ALL
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute myeloid leukemia (AML) enrolled on Children's Oncology Group (COG) studies.

Brief summary: RATIONALE: Diagnostic procedures that find residual disease may help predict if the disease will come back in patients diagnosed with acute myeloid leukemia.

PURPOSE: This research trial studies the comparison of laboratory test results for minimal residual disease in samples from patients with acute myeloid leukemia.

Detailed description: OBJECTIVES:

* To promote harmonization between Cooperative Group Reference Laboratories conducting minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.

OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease studies by flow cytometry. Results are then provided to the National Cancer Institute for assessment and comparability of test results.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Non-identified cryopreserved samples of bone marrow and/or peripheral blood from patients with acute myeloid leukemia (AML) from the Children Oncology Group (COG) studies

  * Baseline/diagnostic AML samples
  * Samples collected after initial treatment and representing varying levels of residual blast counts

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Degree of concordance in the MRD assay results between laboratories
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: National Cancer Institute (NCI)
name: J. Milburn Jessup, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02464202: Use of CBCT-based Tooth Replica in Tooth Autotransplantation to Improve the Outcome of Tooth Replacement in Children
Official title: Use of Stereolithographic Model in Tooth Autotransplantation and Periodontal Ligament Stem Cells for Pulp Revascularization and Reinnervation to Increase the Success Rate for Tooth Replacement in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Increase Success Rate of Tooth Transplantation
Keywords: Tooth autotransplantation
stereolithography tooth replica
CBCT
Outcome
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: Research Foundation Flanders
First posted: 2015-06-08
Enrollment: 100
Sex: ALL
Minimum age (years): 9
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study lies in comparing the outcome of the proposed technique in a large sample size group to the outcome of the conventional tooth autotransplantation method and to provide sufficient evidence for improving the long-term success rate of the tooth autotransplantation procedure.


Eligibility criteria: Inclusion Criteria:

The subjects will be divided in two groups according to different surgical protocols.

1. Pediatric subjects (age between 9-18 years) treated with the CBCT-based replica procedure (prospective approach).

   Pediatric subjects (N=50) that missed their teeth due to agenesis or lost their permanent teeth due to trauma, caries, and endodontic failure and referred to dentistry department for replacement of the missing tooth by means of tooth autotransplantation.
2. Pediatric subjects (age between 9-18 years) treated with the conventional method (prospective and retrospective).

Pediatric subjects (N=50) that missed their teeth due to agenesis or lost their permanent teeth due to trauma, caries, and endodontic failure and referred to dentistry department for replacement of the missing tooth by means of tooth autotransplantation.

A matched control patient will be selected with the focus on a very similar surgical challenge, based on age, gender and a matching donor tooth with the same stage of root development and host bed.

Exclusion Criteria:

* Potential participants (case and control) will be excluded if follow-up data are missing for the one-year follow-up.

Primary outcomes:
measure: success rate
timeFrame: 5 years
measure: survival rate
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: KULeuven
Study officials:
References:
citation: EzEldeen M, Wyatt J, Al-Rimawi A, Coucke W, Shaheen E, Lambrichts I, Willems G, Politis C, Jacobs R. Use of CBCT Guidance for Tooth Autotransplantation in Children. J Dent Res. 2019 Apr;98(4):406-413. doi: 10.1177/0022034519828701. Epub 2019 Feb 20.
Clinical trial NCT00654602: 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
Official title: A 48 Week, Open Label, Non-Comparative, Multicentre, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolaemia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dyslipidaemia
Keywords: cholesterol
low density lipoproteins
dyslipidaemia
Rosuvastatin
Crestor
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-08
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.


Eligibility criteria: Inclusion Criteria:

* Fasting low density lipoprotein level as defined by the protocol.
* Fasting triglyceride level as defined by the protocol.

Exclusion Criteria:

* The use of lipid lowering drugs or dietary supplements after Visit 1.
* Active arterial disease eg Unstable angina, or recent arterial surgery.
* Blood lipid levels above the limits defined in the protocol.
* Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

Primary outcomes:
measure: Reduction in low density lipoprotein cholesterol levels
timeFrame: 12 weeks
Secondary outcomes:
measure: Reduction in low density lipoprotein cholesterol levels
timeFrame: 24 & 48 weeks
measure: Safety: adverse events & abnormal laboratory markers
timeFrame: 4 weekly until week 12 then 12 weekly thereafter.
measure: Maintenance of lowered low density lipoprotein cholesterol level
timeFrame: Between week 12-48
Other outcomes:
Locations:
Study officials:
affiliation: Metabolic & Athersclerotic research centre, USA
name: Dr. Evan Stein
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca
name: Russell Esterline
role: STUDY_DIRECTOR
References:
Clinical trial NCT05868902: A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.
Official title: A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Coronary; Ischemic
Keywords: Magnetocardiography
Coronary Ischemia
Lead sponsor: Genetesis Inc.
Sponsor class: INDUSTRY
First posted: 2023-05-22
Enrollment: 300
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men and women age 40 and up with suspected or confirmed coronary ischemia who are scheduled to undergo diagnostic cardiac PET, for non-emergent diagnostic purposes at an enrolling clinical trial center.

Brief summary: A multicenter observational data development registry collecting diagnostic measures via standard of care (SOC) cardiac PET in order gain a better understanding of how CardioFlux MCG may be used in the detection of coronary ischemia.


Eligibility criteria: Inclusion Criteria:

* Willing to provide informed consent
* Male or female, aged 40 and up (inclusive) at the time of enrollment
* Clinical suspicion of myocardial ischemia that clinician desired cardiac PET
* Completed cardiac PET within 2 weeks prior to study enrollment

Exclusion Criteria:

* Patients unable to fit into CardioFlux device.
* Patients unable to lie supine for 5 minutes.
* Patients with implanted ferromagnetic objects above the costal margin of the rib cage (implanted pacemakers, cardioverter/defibrillators, infusion pumps, and/or neuro stimulators). NOTE: Sternotomy wires stents are acceptable
* Ongoing atrial fibrillation or atrial flutter
* Life expectancy \<1 yrs. due to non-cardiovascular comorbidity

Primary outcomes:
measure: To collect diagnostic data using SOC diagnostic cardiac PET testing for the purposes of gaining a better understanding of how CardioFlux MCG may be used in the detection of coronary ischemia
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Kettering
country: United States
facility: Kettering Health
state: Ohio
Study officials:
References:
Clinical trial NCT00005102: Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome
Official title: Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: DiGeorge Syndrome
Shprintzen Syndrome
Chromosome Abnormalities
Abnormalities, Multiple
Conotruncal Cardiac Defects
Keywords: DiGeorge syndrome
Shprintzen syndrome
cardiovascular and respiratory diseases
conotruncal cardiac defects
genetic diseases and dysmorphic syndromes
rare disease
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
Collaborators: name: Children's Hospital of Philadelphia
First posted: 2000-04-07
Enrollment: 11
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: NATURAL_HISTORY

Brief summary: OBJECTIVES:

I. Determine the pattern of immunologic reconstitution in patients with T-cell compromise due to DiGeorge syndrome or velocardiofacial syndrome.

II. Determine any correlation between immunologic function in these patients and chromosome 22 deletion breakpoints.

III. Determine presence of sustained immunologic compromise in older patients.

Detailed description: PROTOCOL OUTLINE:

Blood samples are collected at diagnosis of chromosome 22q11 deletion and assessed for lymphocyte proliferation in response to mitogens phytohemagglutinin, pokeweed mitogen, and concanavalin A (mitogen stimulation analyses). These analyses are repeated at 4 months along with a quantitative analysis of immunoglobulin.

At 8 months, patients are tested for their lymphocytes' ability to respond to antigens (candida, tetanus, and diphtheria). At 1 year, patients have lymphocyte subset, IgG, IgA, and IgM analyses performed. Quantitative evaluations of antibody titers to diphtheria, tetanus, Haemophilus influenza, and hepatitis B are also performed.

Over 1 year of age, all studies are performed if the patient is seen for a single visit.

Eligibility criteria: * Conotruncal cardiac lesion to be repaired by surgery AND Chromosome 22q11 deletion by FISH

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Kathleen E. Sullivan
role: STUDY_CHAIR
References:
Clinical trial NCT06543602: the Multi-modal Evaluation of Agitation in Critically Ill Patients Based on Remote Video-Ultra-sensitive Detection Wave
Official title: A Multi-modal Recognition Model and Efficacy Evaluation for Agitation Behavior in Critically Ill Patients Based on Remote -Ultra-sensitive Detection Wave ---A Multi-center, Open-label, Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Critically Ill Patients
Keywords: Critically Ill
agitation
monitoring
remote
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
Collaborators: name: People's Hospital of Quzhou
name: The Second Affiliated Hospital of Jiaxing University
name: Zhoushan Hospital of Zhejiang
name: Longquan People's Hospital
name: Fuyang District First People's Hospital of Hangzhou
name: The Third Affiliated Hospital of Wenzhou Medical University
First posted: 2024-08-09
Enrollment: 580
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: any patients with agitation

Brief summary: The goal of this observational study is to learn about the effectiveness of the multi-modal evaluation for agitation behavior in critically ill patients based on remote video-Ultra-sensitive detection wave.

The main question it aims to answer is: evaluate the effectiveness of multi-modal evaluation monitoring system for agitated critically ill patients Participants already taking multi-modal evaluation monitoring system as part of their regular medical care for agitated critically ill patients will compare their effectiveness for agitation for 3 years.


Eligibility criteria: Inclusion Criteria:

* Patients at risk of agitation in the ICU
* Patients with RASS score -2 and above
* ≦ 65 years old, ≧ 18 years old

Exclusion Criteria:

* The affected party refused to participate in this study
* Missing/incomplete information
* Vulnerable groups such as pregnant women, those who lack the capacity for civil conduct and do not have the consent of their legal representatives
* Maxillofacial trauma, burns, tumors, surgery, etc. affect facial expression
* Patients with limb impairment and amputation
* Spinal cord injury, limb movement/sensory limitations
* Patients with pre-existing neurological/psychiatric diseases
* Patients with malignant tumors
* Patients with infectious diseases
* Patients with terminal disease and dying disease
* Abnormal behavior due to head injury or craniocerebral disease

Primary outcomes:
measure: the correct rate for alerting agitated critically ill patients
timeFrame: 10-15 seconds every agitated patients during stay in ICU
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: the second affiliated hospital, Zhejiang University school of medicine
state: Zhejiang
city: Hanzhou
country: China
facility: SAHZU
state: Zhejiang
Study officials:
References:
Clinical trial NCT02201121: Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation
Official title: Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Circulation
Drug Dose
Calculated SAP
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2014-07-25
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Although induced hypertension decreased SVV and PPV,the influences of stroke volume variation and pulse pressure variation caused by phenylephrine,dopamine and ephedrine were unknown.

Detailed description: Pulse pressure variation (PPV) and stroke volume variation (SVV) during mechanical ventilation have been shown to be effective parameters to predict preload responsiveness. Although induced hypertension decreases PPV and SVV, the influences of phenylephrine, dopamine and ephedrine on PPV and SVV are unknown.

Eligibility criteria: Inclusion Criteria:

* Their American Society of Anesthesiologists (ASA) physical status was 1 or 2
* Body mass index (BMI) ranged from 18 to 26
* None of the patients had known diabetes mellitus, hypertension, cardiovascular, pulmonary, endocrinological, neurological diseases, or diseases that influenced intravascular fluid volume or balance
* All patients had a preoperative fast for at least 8 h and routine atropine intramuscular injection

Exclusion Criteria:

* Persistent arrhythmias
* Intraoperative application of vasoactive drugs except phenylephrine, dopamine and ephedrine

Primary outcomes:
measure: invasive arterial blood pressure as a Measure of Safety
timeFrame: DAY 1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00784121: Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility
Official title: Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Breeze Pocket BR.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hygiene
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-11-02
Enrollment: 54
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Breeze (Lactic Acid) Pocket BR.


Eligibility criteria: Inclusion criteria:

* Age between 18 and 60 years old;
* Phototype Skin I,II, III e IV
* Integral skin test in the region;
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

* Lactation or gestation
* Use of Antiinflammatory and/or immunosuppression drugs one month before the study;
* Personal history of atopy;
* History of sensitivity or irritation for topic products;
* Active cutaneous disease;
* Use of new drugs or cosmetics during the study;

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.
timeFrame: Throughout the study
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Jaderson Lima
role: STUDY_DIRECTOR
References:
Clinical trial NCT00825721: Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
Official title: A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Nuclear Cataract
Keywords: Cataract Study
Ophthalmic Study
Agerelated cataract
Nuclear Cataract
Low grade nuclear cataracts
Lead sponsor: Chakshu Research, Inc.
Sponsor class: INDUSTRY
First posted: 2009-01-21
Enrollment: 81
Sex: ALL
Minimum age (years): 35
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract


Eligibility criteria: Inclusion Criteria:

* Presence of nuclear sclerosis cataract
* BCDVA within the range of 20/40 and 20/80

Exclusion Criteria:

* Any other clinical condition in the eye that may compromise vision
* Presence or history of glaucoma
* Presence or history of diabetes
* Use of eyedrops
* Use of steroids

Primary outcomes:
measure: Best-corrected visual acuity by ETDRS
timeFrame: 360 days
Secondary outcomes:
Other outcomes:
Locations:
city: Kathmandu
country: Nepal
facility: Tilganga Eye Center
Study officials:
affiliation: Tilganga Eye Center
name: Sanduk Ruit, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tilganga Eye Center
name: Reeta Gurung, MD
role: PRINCIPAL_INVESTIGATOR
References: